Type 2

CureusCardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-AnalysisType 2 diabetes mellitus (T2DM) markedly increases the risk of cardiovascular and renal complications, emphasizing the need for therapies….1 hour ago

News Source0307 views

CureusCardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-AnalysisType 2 diabetes mellitus (T2DM) markedly increases the risk of cardiovascular and renal complications, emphasizing the need for therapies….1 hour ago

Related posts

Kyoto University unveils noninvasive assessment for diabetes

Association of Neutrophil-to-Lymphocyte Ratio With Early Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus

Dexcom unveils Type 2 diabetes CGM data at ATTD